Membership benefits

Early Access

to latest news and research articles
Members have free and unrestricted access to papers immediately after publication

Members' Services

CES offers free or discounted access to several platforms
Journal subscriptions, publication fees, annual meetings, reagents from industry partners, job postings & more


Eligibility for the Cancer Epigenetics Society Awards
Members can exclusively nominate and be recipients of the Epi Awards

Members' Resources

CES offers several resources to scientists & patients
Several cancer epigenetics databases, meetings, grant & job listings, and continuously expanding resources for scientists & patients

Our databases & journals

Our latest video

The latest news from CES databases & journals

01/09/2017- Dr. Tatiana Kutateladze, Professor of Pharmacology at the University of Colorado School of Medicine (Aurora, CO, USA) is Editor at Cancer Epigenetics
12/21/2016-Dr. Luciano Di Croce, Head of Epigenetics Events in Cancer Group at the Centre for Genomic Regulation (CGR) at the Barcelona Institute of Science and Technology (Barcelona, Spain) is Editor at Cancer Epigenetics
12/15/2016-Cancer Epigenetics Drug Database now includes four families of epigenetic-targeting drugs
12/9/2016-Dr. Giacomo Cavalli, Head of Chromatin & Cell Biology Laboratory, Institute for Human Genetics (Montpellier, France) & member of the EpigeneSys Network of Excellence, is Editor at Cancer Epigenetics
11/28/2016-Dr. Jonathan D. Licht, Director of University Florida Health Cancer Center, Gainesville (FL, USA) & Dana-Farber SPORE in Myeloma Investigator, is Editor at Cancer Epigenetics

Latest Scientific Cancer Epigenetics News

Latest Medical Cancer Epigenetics News

FDA approves first colorectal cancer screening blood test: the first blood test to detect colorectal cancer approved by the US Food and Drug Administration (FDA) is a cancer epigenetics diagnostic test developed by Epigenomics AG, a German medical diagnostics company that specializes in colorectal and lung cancers. The test detects DNA methylation of Septin 9 (SEPT9), a gene on chromosome 17 whose product controls cytokinesis and cell cycle, which may serve as a tumor suppressor in ovarian cancer, and which is associated to colorectal cancer. The cancer epigenetics diagnostic test offers a minimally invasive alternative to patients who may not be comfortable undergoing a colonoscopy. The diagnostic kit dubbed Epi proColon® was already approved for use in Argentina, China, Europe, and Hong Kong (Cancer Epigenetics Society; medical news).

The Cancer Epigenetics Society in numbers

Society Members:

Continents covered
Affiliate Members
Biomedical MD/PhD Students
Biomedical MD/PhDs

Latest Cancer Epigenetics Society members

Fay Christodoulou (Chief Scientific Officer), Miroculus, San Francisco, CA, USA
Sumit Deswal (Postdoctoral Fellow), Research Institute of Molecular Pathology, Vienna, Austria
Krishnaswamy Kannan (Director), Biomolecular Integrations & University of Arkansas for Medical Sciences, Little Rock, AR, USA
Tibor Pankotai (Assistant Professor), Department of Biochemistry & Molecular Biology, Genome Integrity & DNA Repair Group, Szeged, Csongrad, Hungary
Jean Hausser (Postdoctoral Fellow), Department of Molecular & Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Željko Svedružić (Assistant Professor), Faculty of Medicine, University of Rijeka, Rijeka, Croatia
Sunil J. Raja (Group Leader), Department of RNA Biology, Silence Therapeutics, Berlin, Germany
Alexandra Kalmar (Associate Professor), Department of Medical Genetics, Faculty of Medicine, Near East University, Nicosia, Cyprus
Victoria Bulat (Clinical Research Coordinator), N. N. Alexandrov Oncology Center, Lesnoy, Belarus
Anindya Bagchi (Associate Professor), University of Minnesota, Minneapolis, MN, USA

Society Web Portal Contents:

Research grants
Epigenetic modifiers
Scientific meetings
Epigenetics drugs
Advocacy & Support groups
Cancers & other neoplasms
Cancer epigenetics clinical trials
Cancer cell lines
Cancer epigenetics experiments